Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination
therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer. These
are subjects who are newly diagnosed advanced or metastatic hormone receptor positive breast
cancer or subjects who have progressed following treatment free interval of more than 12
months following adjuvant or neoadjuvant treatment.